Jared Kaltwasser

A new study that looks at the long-term effects of dimethyl fumarate finds the therapy is safe and effective in patients with relapsing-remitting multiple sclerosis who have taken the therapy for approximately a decade.

Psoriatic arthritis and psoriasis both place a significant economic burden on patients, but a new analysis shows the burden on people with the former is significantly higher.

The bruton tyrosine kinase inhibitor zanubrutinib was shown to generate high response rates in a new study of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

A new report shows just how much disease modifying therapies (DMTs) have changed the economic landscape of treating multiple sclerosis.

Five metabolic inhibitors appear to have strong antiproliferative effects on acute myeloid leukemia (AML), according to a new study.

Identifying the particular genes at play in multiple sclerosis (MS) could lead to a better understanding of the disease, and possibly better therapies for it. A new paper proposes network representation learning as the best method to identify those genes.

Some oncologists refrain from prescribing checkpoint immunotherapy in patients with Kaposi sarcoma who also have psoriasis or other skin conditions. A new case report says the therapy can be successfully completed while still controlling the skin condition.

It’s rare for a patient to be diagnosed with both acute myeloid leukemia and multiple myeloma at the same time, but a new case study suggests there are options to treat both diseases at the same time in such cases.

Patients who are treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia are at a higher risk of a secondary malignancy. A new case study suggest the list of potential secondary malignancies should include lymphoplasmacytic lymphoma.

A new study based on interviews with families and patients undergoing chronic transfusion therapy for sickle cell disease finds that the therapy affects the families in ways that extend beyond health.

A new analysis of patients with early multiple sclerosis (MS) suggests they universally carry antibodies for Epstein-Barr virus, a virus increasingly thought to be linked to MS.

New data suggests white patients who are deficient in vitamin D have lower rates of survival when diagnosed with multiple myeloma. The phenomenon was not seen, however, in African American patients.

A new report on 3 rare cases of patients with myeloproliferative neoplasms who developed T-cell malignancies sheds light on red flags clinicians should look for.

A new large-scale study of patients with myeloproliferative neoplasm finds they are at twice the risk of mortality from respiratory disease.

New research suggests disparities in incidence and survival rates in multiple myeloma may have a lot to do with healthcare quality and access to care.

Clinicians treating patients with multiple myeloma have a number of factors to consider as they treat patients in an era of high-risk COVID-19 infection.

New research could make it easier to find out which patients are mostly likely to go on to develop multiple myeloma. The findings could have implications for therapeutic interventions.

Chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) is rare, making it difficult to differentiate from other types of lymphoma. A new study helps explain key unique traits.

A new review article finds patients who suffer from psoriatic arthritis (PsA) face a higher risk of type 2 diabetes (T2D), though the exact reasons for the linkage are not yet clear.

A new pooled analysis of rituximab/bendamustine and rituximab/cytarabine in transplant-eligible patients with mantle cell lymphoma (MCL) finds it leads to durable positive results in most patients.

Investigators still have a lot to learn about the links among psoriatic arthritis, inflammation, and depression, but a growing body of evidence suggests significant interplay.

Artificial intelligence and deep learning have advanced to the point where they can play a significant role in cancer care, but fully integrating the technology into the clinic remains a challenge.

A new article outlining the experience of a patient with a history of multiple myeloma (MM) who contracted coronavirus disease 2019 (COVID-19) shows the interleukin-6 receptor inhibitor tocilizumab was an effective therapy.

A range of new research is helping scientists better understand psoriasis while also raising new questions. One approach is looking at how the gut microbiome affects the disease.

Patients with lymphoma have better odds of survival now than they did 20 years ago, according to new research. The data also help explain which types of cancer continue to be the most challenging.

A number of advances have been made in recent years in our understanding of the genetics of psoriatic diseases and psoriatic arthritis specifically. However, those advances have yet to translate into clinically meaningful insights.

A new study based on treatment of patients with chronic lymphocytic leukemia (CLL) in mostly community settings challenges earlier findings about the superiority of a common therapeutic approach and also makes a strong case for ibrutinib.

As more patients with heart disease live longer, physicians need better tools to assess frailty in those with heart failure. New study results suggest a multidimensional assessment approach is preferable to one that focuses only on physical metrics.

Investigators trying to find a way to stop antigen loss following CD19 CAR T cell therapy found an approach simultaneously targeting CD19 and CD22 is safe and feasible.

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy.